Zoetis news
The WiseView Research desk's stories that name Zoetis, the latest headlines about it, and the trades members of Congress and company insiders have disclosed. The ZTS page →
- HeadlineZoetis (ZTS) Registers a Bigger Fall Than the Market: Important Facts to Note
- HeadlineZTS vs. ICCC: Which Animal Health Stock Is the Better Investment Bet?
- HeadlineZoetis Receives FDA Approval for Convenia® RTU for Dogs (cefovecin injectable suspension), Helping More Medium and Large Dogs Access Single-Injection Treatment
- HeadlineZoetis Appoints Iris Knobloch to its Board of Directors
- CongressGilbert Cisneros bought $1,001 - $15,000 of ZTS
- HeadlineZoetis (ZTS) Outpaces Stock Market Gains: What You Should Know
- CongressRo Khanna bought $1,001 - $15,000 of ZTS
- CongressRo Khanna sold $1,001 - $15,000 of ZTS
- CongressRo Khanna sold $1,001 - $15,000 of ZTS
- HeadlineZoetis Declares Fourth Quarter 2026 Dividend
- HeadlineNew Peer-Reviewed Publication on Laboratory Study That Demonstrated Simparica Trio® Protected 3x More Dogs From Infection With a Resistant Heartworm Isolate Than NexGard® Plus1
- HeadlineZoetis (ZTS) Stock Sinks As Market Gains: Here's Why
- HeadlineZoetis: Priced For The Worst, Worth Buying
- CongressGilbert Cisneros sold $1,001 - $15,000 of ZTS
- CongressRo Khanna bought $1,001 - $15,000 of ZTS
- CongressByron Donalds bought $1,001 - $15,000 of ZTS
- CongressGilbert Cisneros bought $1,001 - $15,000 of ZTS
Headlines link to their publishers. Members of Congress disclose ranges, not exact amounts, and may file weeks after the trade; insider filings are open-market purchases and sales from SEC Form 4. For information only, not investment advice.